Patent: ROS-detonable Nanoclusters for Anti-Restenotic Therapy

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted a patent (US12582613B2) for biomimetic, reactive oxygen species-detonable nanoclusters designed for anti-restenotic therapy. The technology, assigned to the University of Virginia Patent Foundation, involves nanoclusters with self-assembled cores and biomimetic membrane coatings that can deliver anti-restenotic drugs.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582613B2 for a novel therapeutic approach involving ROS-detonable nanoclusters. The patent, assigned to the University of Virginia Patent Foundation, covers nanoclusters comprising self-assembled unimolecular nanoparticle cores surrounded by biomimetic membrane coatings. These nanoclusters are designed to treat and prevent restenosis, potentially containing anti-restenotic drugs. The technology leverages reactive oxygen species (ROS) present at sites of vascular damage to cleave hydrophobic groups on the nanoclusters, increasing their hydrophilicity and enabling greater tissue penetration.

This patent grant signifies the issuance of a new intellectual property right for a specific medical technology. While not a regulatory rule imposing obligations on companies, it represents a novel therapeutic development in the field of cardiovascular disease treatment. Companies involved in drug delivery systems, nanomedicine, or cardiovascular therapies should be aware of this patented technology, particularly if their research or product development overlaps with anti-restenotic treatments or ROS-responsive drug delivery mechanisms. No immediate compliance actions are required for regulated entities based solely on this patent grant.

Source document (simplified)

← USPTO Patent Grants

Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy

Grant US12582613B2 Kind: B2 Mar 24, 2026

Assignee

University of Virginia Patent Foundation

Inventors

Kenneth Craig Kent, Lian-Wang Guo, Bowen Wang, Takuro Shirasu, Shaoqin Gong, Yi Zhao

Abstract

In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.

CPC Classifications

A61K 9/5176 A61K 9/5146 A61K 31/517 A61K 35/19 A61K 9/0019 A61K 9/5068 A61K 9/5153 A61K 31/337 A61K 31/551 A61K 31/573 A61K 45/06 A61K 31/5517 A61P 9/14 A61P 9/00